Canada At BIO 2019

Thank you to the Canada pavilion partners

Invest in Canada BioTalent Canada
Government of Quebec Caprion Biosciences
LifeSciences British Columbia National Research Council of Canada
BioAlberta VWR, Part of Avantor
Atlantic Canada Global Affairs Canada
PEI BioAlliance Medicago

Canada remained the largest international delegation on the show floor throughout the BIO International Convention in Philadelphia (June 3-6), with nearly 800 Canadian delegates, the Canadian pavilion was the natural home away from home with BIOTECanada once again providing members with important networking opportunities. Each year the industry uses the opportunity to showcase how important it is for industry and government to work in partnership to advance the Canadian biotech sector. Planning is already underway for BIO 2020 June 8 – 11 taking place in San Diego. If interested in participating please contact Shaely Williams.

CDRD & NEOMED INstitute join forces to create a new pan-canadian enterprise admare bioinnovations

ad_mare_toastFrom left to right: Andrew Casey (President and CEO BIOTECanada), Alan Winters (BC Innovation Commissioner), Gordon McCauley (CEO AdMare), Pierre Fitzgibbon (Minister of Economy and Innovation), and John Knubley (Deputy Minister, Innovation, Science, and Economic Development). 

Two successful Canadian innovation organizations, CDRD, Canada’s national life sciences venture, and NEOMED Institute, a leading not-for-profit R&D organization building an innovation ecosystem in Montréal, are pleased to announce that effective today, they are bringing their respective capabilities and resources together under a new co-founded pan-Canadian enterprise, adMare BioInnovations. Learn more.

Innovation Nation Investment Panel

invest_panel_2The Canadian biotechnology sector is a great example of how research, innovation and entrepreneurship within a healthy ecosystem can produce some truly remarkable innovations and companies with enormous potential to fundamentally change lives and economies. Foreign direct investment plays an absolutely critical role in fueling Canadian biotech innovation. Canada must compete against the rest of the world for those investment dollars. The panel explored the economic opportunity of biotech innovation and Canada’s strengths and weaknesses with respect to attracting investment.

Elizabeth Douville, Co-Founder and General Partner, AmorChem II Ventures
John Knubley, Deputy Minister, Innovation, Science and Economic Development
Ian McKay, CEO, Invest in Canada
Michal Preminger, PhD, MBA Head, Johnson & Johnson Innovation, East North America
Oliver Technow, President, BioVectra
Moderated by Andrew Casey, President and CEO, BIOTECanada

Digital Therapeutics: The Marriage of Technology and Medicine


From left to right: Natalie Dakers (Accel-Rx), Megan Coder (Digital Therapeutics Alliance), Antoun Nabhan (Pear Therapeutics), and Rachel Sha (Sanofi)
Perspectives on The Future of Medicine
It’s disruptive. It’s cutting edge. And it’s going to take the world of health by storm.
Accel-Rx was pleased to host a panel at BIO 2019 to share best practices and lessons learned from leaders in digital therapeutics. Here’s one key takeaway to live by: There is a lot going on in digital therapeutics in the rest of the world, and Canada can benefit by learning from the experiences of others who are already marching down the digital path.
Thank you to the Digital Therapeutics AlliancePear Therapeutics and Sanofi for sharing your expertise! Watch the video of the panel session to learn more.